CN110650748B - 与经工程改造的Fc构建体相关的组合物和方法 - Google Patents

与经工程改造的Fc构建体相关的组合物和方法 Download PDF

Info

Publication number
CN110650748B
CN110650748B CN201880016496.8A CN201880016496A CN110650748B CN 110650748 B CN110650748 B CN 110650748B CN 201880016496 A CN201880016496 A CN 201880016496A CN 110650748 B CN110650748 B CN 110650748B
Authority
CN
China
Prior art keywords
seq
domain
polypeptide
sequence
domain monomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880016496.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN110650748A (zh
Inventor
C.J.博斯克斯
J.C.兰辛
D.奥尔蒂斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Momenta Pharmaceuticals Inc
Original Assignee
Momenta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Momenta Pharmaceuticals Inc filed Critical Momenta Pharmaceuticals Inc
Priority to CN202311710523.0A priority Critical patent/CN117886928A/zh
Publication of CN110650748A publication Critical patent/CN110650748A/zh
Application granted granted Critical
Publication of CN110650748B publication Critical patent/CN110650748B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
CN201880016496.8A 2017-01-06 2018-01-05 与经工程改造的Fc构建体相关的组合物和方法 Active CN110650748B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202311710523.0A CN117886928A (zh) 2017-01-06 2018-01-05 与经工程改造的Fc构建体相关的组合物和方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762443495P 2017-01-06 2017-01-06
US62/443495 2017-01-06
US201762510228P 2017-05-23 2017-05-23
US62/510228 2017-05-23
US201762589473P 2017-11-21 2017-11-21
US62/589473 2017-11-21
PCT/US2018/012488 WO2018129255A1 (en) 2017-01-06 2018-01-05 Compositions and methods related to engineered fc constructs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202311710523.0A Division CN117886928A (zh) 2017-01-06 2018-01-05 与经工程改造的Fc构建体相关的组合物和方法

Publications (2)

Publication Number Publication Date
CN110650748A CN110650748A (zh) 2020-01-03
CN110650748B true CN110650748B (zh) 2024-01-02

Family

ID=62791103

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880016496.8A Active CN110650748B (zh) 2017-01-06 2018-01-05 与经工程改造的Fc构建体相关的组合物和方法
CN202311710523.0A Pending CN117886928A (zh) 2017-01-06 2018-01-05 与经工程改造的Fc构建体相关的组合物和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202311710523.0A Pending CN117886928A (zh) 2017-01-06 2018-01-05 与经工程改造的Fc构建体相关的组合物和方法

Country Status (10)

Country Link
US (3) US11220531B2 (enExample)
EP (1) EP3565588A4 (enExample)
JP (2) JP7146771B2 (enExample)
KR (1) KR102624254B1 (enExample)
CN (2) CN110650748B (enExample)
AU (1) AU2018205808B2 (enExample)
BR (1) BR112019013955A2 (enExample)
CA (1) CA3049383A1 (enExample)
SG (2) SG11201906139VA (enExample)
WO (1) WO2018129255A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106661125B (zh) * 2014-05-02 2021-10-01 动量制药公司 涉及工程化Fc构建体的组合物和方法
US12391759B2 (en) 2016-03-02 2025-08-19 Momenta Pharmaceuticals, Inc. Methods related to engineered Fc constructs
KR102635635B1 (ko) * 2016-05-23 2024-02-14 모멘타 파머슈티컬스 인코포레이티드 유전자 조작 Fc 작제물에 관한 조성물 및 방법
CN110650748B (zh) 2017-01-06 2024-01-02 动量制药公司 与经工程改造的Fc构建体相关的组合物和方法
KR20220062084A (ko) 2019-09-13 2022-05-13 체에스엘 베링 렝나우 아게 면역 복합체 매개된 콩팥 장애의 치료를 위한 재조합 IgG Fc 다량체
JP2023505493A (ja) 2019-12-06 2023-02-09 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト Ｆｃ多量体の安定組成物
GB202005879D0 (en) * 2020-04-22 2020-06-03 Petmedix Ltd Heterodimeric proteins

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2556219B1 (fr) 1983-12-07 1987-06-26 Merieux Inst Nouveau medicament immunomodulateur, a base de fragments fc d'igg humaines
US5426641A (en) 1994-01-28 1995-06-20 Bell Communications Research, Inc. Adaptive class AB amplifier for TDMA wireless communications systems
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
AU3804397A (en) 1996-06-14 1998-01-07 Smithkline Beecham Corporation Hexameric fusion proteins and uses therefor
US20090074839A1 (en) 1997-01-22 2009-03-19 Marton Milankovits Pharmaceutical Compositions Primarily for the Treatment and Prevention of Genitourinary Infections and their Extragenital Complications
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US7951917B1 (en) 1997-05-02 2011-05-31 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
WO2001045746A2 (en) 1999-12-24 2001-06-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
US20050089932A1 (en) 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
WO2005077981A2 (en) 2003-12-22 2005-08-25 Xencor, Inc. Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
JP5620626B2 (ja) 2005-03-31 2014-11-05 中外製薬株式会社 会合制御によるポリペプチド製造方法
GB0614780D0 (en) 2006-07-25 2006-09-06 Ucb Sa Biological products
WO2008088422A2 (en) 2006-10-25 2008-07-24 Amgen Inc. Toxin peptide therapeutic agents
BRPI0620639A2 (pt) 2006-12-21 2011-11-22 Micromet Ag anticorpos de cadeia simples biespecìficos e composição farmacêutica compreendendo os mesmos
US20080260738A1 (en) 2007-04-18 2008-10-23 Moore Margaret D Single chain fc, methods of making and methods of treatment
BRPI0811857A2 (pt) 2007-05-14 2014-10-21 Biogen Idec Inc Regiões fc (scfc) de cadeia simples, polipeptídeos de aglutinação que as compreendem e métodos relacionados.
EP2185589B1 (en) 2007-06-01 2016-01-06 University of Maryland, Baltimore Immunoglobulin constant region fc receptor binding agents
PT2235064E (pt) 2008-01-07 2016-03-01 Amgen Inc Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática
SG189730A1 (en) 2008-04-02 2013-05-31 Macrogenics Inc Her2/neu-specific antibodies and methods of using same
WO2010042481A1 (en) 2008-10-06 2010-04-15 University Of Chicago Compositions and methods related to bacterial eap, emp, and/or adsa proteins
US20100143353A1 (en) 2008-12-04 2010-06-10 Mosser David M POLYPEPTIDES COMPRISING Fc FRAGMENTS OF IMMUNOGLOBULIN G (lgG) AND METHODS OF USING THE SAME
CA2747011C (en) * 2008-12-18 2018-06-19 Dana-Farber Cancer Institute, Inc. Nkg2d-fc for immunotherapy
AU2010206681A1 (en) 2009-01-23 2011-09-01 Biogen Idec Ma Inc. Stabilized Fc polypeptides with reduced effector function and methods of use
WO2010135534A2 (en) 2009-05-20 2010-11-25 Children's Medical Center Corporation Compositions for the treatment of metastatic cancer and methods of use thereof
EP2432803A2 (en) 2009-05-20 2012-03-28 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
JP5683581B2 (ja) 2009-06-30 2015-03-11 リサーチ ディベロップメント ファウンデーション 免疫グロブリンＦｃポリペプチド
CA2781519A1 (en) 2009-09-16 2011-03-24 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
KR101808602B1 (ko) 2009-10-07 2017-12-13 마크로제닉스, 인크. 푸코실화 정도의 변경으로 인해 개선된 이펙터 기능을 나타내는 Ｆｃ 영역-함유 폴리펩티드, 그것의 사용 방법
EP2504360B1 (en) 2009-11-23 2018-08-15 Amgen Inc. Monomeric antibody fc
GB0922209D0 (en) 2009-12-18 2010-02-03 Univ Nottingham Proteins, nucleic acid molecules and compositions
JP6200806B2 (ja) 2010-05-21 2017-09-20 メリマック ファーマシューティカルズ インコーポレーティッド 二重特異的融合タンパク質
WO2012006635A1 (en) 2010-07-09 2012-01-12 Biogen Idec Hemophilia Inc. Processable single chain molecules and polypeptides made using same
MX368531B (es) 2010-07-28 2019-10-07 Gliknik Inc Proteinas de fusion de fragmentos de proteinas humanas naturales para crear composiciones de fc de inmunoglobulinas multimerizadas ordenadamente.
US20130177555A1 (en) 2010-08-13 2013-07-11 Medimmune Limited Monomeric Polypeptides Comprising Variant FC Regions And Methods Of Use
RU2604490C2 (ru) 2010-11-05 2016-12-10 Займворкс Инк. ДИЗАЙН УСТОЙЧИВОГО ГЕТЕРОДИМЕРНОГО АНТИТЕЛА С МУТАЦИЯМИ В Fc ДОМЕНЕ
BR112013023653A2 (pt) 2011-03-17 2016-12-13 Univ Ramot anticorpo biespecífico, método de preparação do anticorpo, e composição farmacêutica
SG10201602371VA (en) 2011-03-25 2016-04-28 Glenmark Pharmaceuticals Sa Hetero-dimeric immunoglobulins
CA2875246A1 (en) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Procoagulant compounds
WO2013192131A1 (en) 2012-06-21 2013-12-27 Indiana University Research And Technology Corporation Incretin receptor ligand polypeptide fc-region fusion polypeptides and conjugates with altered fc-effector function
WO2014031646A2 (en) 2012-08-20 2014-02-27 Gliknik Inc. Molecules with antigen binding and polyvalent fc gamma receptor binding activity
CN110894231A (zh) 2012-10-17 2020-03-20 康诺贝林伦瑙有限公司 免疫调节蛋白
CN104558194B (zh) 2013-10-17 2018-04-27 泰州迈博太科药业有限公司 一类抗CD20-Flex双功能融合蛋白、其制备方法及用途
JP2016538283A (ja) * 2013-11-13 2016-12-08 ザイムワークス，インコーポレイテッド Ｅｇｆｒ及び／またはｈｅｒ２を標的にする一価抗原結合性構築物及びその使用
CN106029087A (zh) 2013-12-20 2016-10-12 印第安纳大学研究及科技有限公司 脂质化肠降血糖素受体配体人免疫球蛋白fc区融合多肽
CA2931979A1 (en) * 2014-01-15 2015-07-23 F. Hoffmann-La Roche Ag Fc-region variants with modified fcrn-binding properties
BR112016016416A2 (pt) 2014-01-15 2017-10-03 Hoffmann La Roche VARIANTES DE REGIÕES-"Fc" COM 'FcRn' MODIFICADAS E PROPRIEDADES DE LIGAÇÃO DE PROTEÍNA "A" MANTIDAS
AU2015226101B2 (en) 2014-03-05 2019-08-22 Ucb Biopharma Sprl Multimeric Fc proteins
BR112016020368A2 (pt) 2014-03-05 2018-01-23 Ucb Biopharma Sprl proteínas fc multiméricas
AU2015248785A1 (en) 2014-04-16 2016-11-24 Ucb Biopharma Sprl Multimeric Fc proteins
CN106661125B (zh) 2014-05-02 2021-10-01 动量制药公司 涉及工程化Fc构建体的组合物和方法
NZ726520A (en) 2014-05-29 2018-12-21 Macrogenics Inc Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof
US12391759B2 (en) * 2016-03-02 2025-08-19 Momenta Pharmaceuticals, Inc. Methods related to engineered Fc constructs
KR102635635B1 (ko) 2016-05-23 2024-02-14 모멘타 파머슈티컬스 인코포레이티드 유전자 조작 Fc 작제물에 관한 조성물 및 방법
CN110650748B (zh) 2017-01-06 2024-01-02 动量制药公司 与经工程改造的Fc构建体相关的组合物和方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Fc Engineering of Human IgG1 for Altered Binding to the Neonatal Fc Receptor Affects Fc Effector Functions";Algirdas Grevys等;《The Journal of Immunology》;20150601;第194卷(第11期);参见摘要，第5498页左栏第2段-第5506页右栏第2段 *
"Fc Optimization of Therapeutic Antibodies Enhances Their Ability to Kill Tumor Cells In vitro and Controls Tumor Expansion In vivo via Low-Affinity Activating Fcγ Receptors";Jeffrey B. Stavenhagen等;《Cancer Res》;20070915;第67卷(第18期);参见摘要，第1页右栏第2段-第7页左栏第1段，表1 *

Also Published As

Publication number Publication date
EP3565588A4 (en) 2020-12-16
US11827682B2 (en) 2023-11-28
AU2018205808A1 (en) 2019-07-25
BR112019013955A2 (pt) 2020-02-11
RU2019124710A3 (enExample) 2021-05-26
WO2018129255A1 (en) 2018-07-12
AU2018205808B2 (en) 2025-02-06
CN117886928A (zh) 2024-04-16
JP7146771B2 (ja) 2022-10-04
US20220267388A1 (en) 2022-08-25
JP2020504143A (ja) 2020-02-06
EP3565588A1 (en) 2019-11-13
SG11201906139VA (en) 2019-08-27
KR102624254B1 (ko) 2024-01-12
US20190345206A1 (en) 2019-11-14
CA3049383A1 (en) 2018-07-12
US20240209040A1 (en) 2024-06-27
JP2022191261A (ja) 2022-12-27
JP7611880B2 (ja) 2025-01-10
SG10202107391YA (en) 2021-08-30
CN110650748A (zh) 2020-01-03
US11220531B2 (en) 2022-01-11
RU2019124710A (ru) 2021-02-08
KR20190099333A (ko) 2019-08-26

Similar Documents

Publication Publication Date Title
JP7295301B2 (ja) 操作されたＦｃコンストラクトに関する組成物及び方法
CN110650748B (zh) 与经工程改造的Fc构建体相关的组合物和方法
CN113164591A (zh) 与工程化Fc-抗原结合结构域构建体有关的组合物和方法
CN113164590A (zh) 与靶向CCR4的工程化Fc-抗原结合结构域构建体有关的组合物和方法
RU2816477C2 (ru) КОМПОЗИЦИИ И СПОСОБЫ, СВЯЗАННЫЕ СО СКОНСТРУИРОВАННЫМИ Fc-КОНСТРУКЦИЯМИ
CN113164592A (zh) 与工程化Fc-抗原结合结构域构建体有关的组合物和方法
HK40005981A (en) Compositions and methods related to engineered fc constructs
HK40005981B (en) Compositions and methods related to engineered fc constructs

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant